Chronic liraglutide therapy induces an enhanced endogenous glucagon-like peptide-1 secretory response in early type 2 diabetes.

about

Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.

P2860

Q37676824-22F08FAC-E845-4BE0-B676-A51E3E2657E2

P2860

Chronic liraglutide therapy induces an enhanced endogenous glucagon-like peptide-1 secretory response in early type 2 diabetes.

Item

http://www.wikidata.org/entity/Q48258498

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Chronic liraglutide therapy in ...... onse in early type 2 diabetes.

@en

Chronic liraglutide therapy in ...... onse in early type 2 diabetes.

@nl

type

Item

label

Chronic liraglutide therapy in ...... onse in early type 2 diabetes.

@en

Chronic liraglutide therapy in ...... onse in early type 2 diabetes.

@nl

prefLabel

Chronic liraglutide therapy in ...... onse in early type 2 diabetes.

@en

Chronic liraglutide therapy in ...... onse in early type 2 diabetes.

@nl

P1476

Chronic liraglutide therapy in ...... ponse in early type 2 diabetes

@en

P2093

Bernard Zinman

http://www.w3.org/2001/XMLSchema#string

Caroline K Kramer

http://www.w3.org/2001/XMLSchema#string

Haysook Choi

http://www.w3.org/2001/XMLSchema#string

P2860

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

Attenuated GLP-1 secretion in obesity: cause or consequence?

Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?

Short-term intensified insulin treatment in type 2 diabetes: long-term effects on β-cell function.

Determinants of reversibility of β-cell dysfunction in response to short-term intensive insulin therapy in patients with early type 2 diabetes.

Glycemic variability in patients with early type 2 diabetes: the impact of improvement in β-cell function.

Initial short-term intensive insulin therapy as a strategy for evaluating the preservation of beta-cell function with oral antidiabetic medications: a pilot study with sitagliptin.

The response to short-term intensive insulin therapy in type 2 diabetes.

Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men.

Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.

P304

744-748

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/DOM.12858

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Philip W Connelly

Ravi Retnakaran

P577

2017-02-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28181363

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

Chronic liraglutide therapy induces an enhanced endogenous glucagon-like peptide-1 secretory response in early type 2 diabetes.

about

P2860

P2860

Chronic liraglutide therapy induces an enhanced endogenous glucagon-like peptide-1 secretory response in early type 2 diabetes.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921